What employees are saying
"Spectra Optia is advancing therapeutic apheresis and cell therapy to the next level of care."
David Perez, President & CEO CaridianBCT
Spectra Optia® Apheresis System
Spectra Optia now available for sale in the U.S., Canada, Europe, Middle East, Africa, and Australia!
Advancing therapeutic apheresis and cell therapy to the next level of care
Over the past two decades, you’ve come to depend on the COBE Spectra apheresis system—the Gold Standard in therapeutic apheresis and cell therapy (TA/CT) devices. We want to continue to provide you and your patients with exceptional TA/CT solutions. Over the past few years, we conducted extensive customer research to address your changing needs. We listened to your feedback and the result is the Spectra Optia apheresis system.
CLICK HERE to request more details about the Spectra Optia system.
Robust technology that delivers consistent results
The Spectra Optia system is based on trusted COBE Spectra technology as well as the proven Trima platform. It also provides additional benefits to meet your needs. As the next generation therapeutic apheresis and cell therapy platform, Spectra Optia delivers COBE Spectra system confidence that is designed to enhance:
- Versatility
- Performance
- Patient care
Spectra Optia’s advanced technology and precision allow you to choose how to provide for your patients. The system features:
- Therapeutic Plasma Exchange (TPE)
- Protocols for EMEA*, Australia and select areas of Southeast Asia
- An intuitive graphical user interface (GUI)
- Simplified, ready-to-use disposable tubing sets
- Improved system mobility
- Automated interface management
- Data management
- Worldwide costumer support
*Europe, Middle East and Africa
These unique features provide you with unparalleled versatility, allowing you to spend less time interacting with the system and more time doing what you love—caring for patients.
Find out more about how the Spectra Optia system works.
[ Feedback ]